Squarepoint Ops LLC Spero Therapeutics, Inc. Transaction History

Squarepoint Ops LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.35 - $1.79 $58,591 - $77,687	-43,401 Reduced 35.34%	79,401 $136,000
Q4 2023 Feb 14, 2024	BUY	$1.0 - $1.47 $44,739 - $65,766	44,739 Added 57.31%	122,802 $180,000
Q2 2023 Aug 14, 2023	BUY	$1.42 - $1.95 $110,849 - $152,222	78,063 New	78,063 $113,000
Q3 2022 Nov 14, 2022	BUY	$0.68 - $2.2 $11,167 - $36,130	16,423 New	16,423 $33,000
Q4 2020 Feb 16, 2021	SELL	$11.65 - $22.07 $171,138 - $324,208	-14,690 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$8.96 - $14.12 $131,873 - $207,818	-14,718 Reduced 50.05%	14,690 $164,000
Q2 2020 Aug 14, 2020	BUY	$7.27 - $14.18 $65,568 - $127,889	9,019 Added 44.23%	29,408 $398,000
Q1 2020 May 15, 2020	BUY	$5.27 - $10.41 $12,574 - $24,838	2,386 Added 13.25%	20,389 $165,000
Q4 2019 Feb 14, 2020	BUY	$9.46 - $12.16 $170,308 - $218,916	18,003 New	18,003 $173,000
Q2 2019 Aug 14, 2019	SELL	$10.25 - $14.36 $132,747 - $185,976	-12,951 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$6.26 - $13.31 $81,073 - $172,377	12,951 New	12,951 $166,000

13.9M

200

200

Ticker SPRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,067,500
Market Cap $33M
Description
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to ...

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

Stay updated on Squarepoint Ops LLC with notifications on news.